CD19 and neoplasm: The success of CAR-T cell therapies for the treatment of hematologic malignancies has not only been due to their potency in killing tumor cells but also because of the exquisite nature of the B lineage specific CD19, CD20 and BCMA markers to which their targeting moieties are directed [30–37].